Account
Watchlists
Bookmarks
Pricing
Market Cap
₹ 3,923 Cr
P/E
35.20
Bearish
2
Neutral
8
Bullish
4
Bearish
13
Neutral
8
Bullish
25
Bearish
11
Neutral
0
Bullish
21
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
RPG Life Sciences Limited is an integrated research-based pharmaceutical company, developing and manufacturing branded formulations, global generics, and synthetic APIs. It operates in India and international markets.
The company is a leader in immunosuppressants and has established a strong presence in both domestic and global formulations. It focuses on chronic and specialty therapies, with a robust portfolio in nephrology, rheumatology, oncology, and gastroenterology.
RPG Life Sciences has initiated multiple transformation projects aimed at reducing costs, enhancing quality, and tapping new business opportunities. This includes modernization efforts, capacity expansion, and strategic brand asset building.
Emphasizing sustainability, the company has undertaken initiatives to reduce carbon emissions, enhance energy and water efficiency, and implement waste management practices that align with ESG goals.
In the technological realm, RPG Life Sciences is integrating IoT and digital platforms to optimize manufacturing processes, quality monitoring, and cybersecurity, driving better efficiency and compliance.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
3,923 Cr
High Risk
35.2
30.8
0.7
7.1
2,715.90
1,772.05
Sales CAGR
1Y
12.26%
3Y
14.08%
5Y
11.71%
10Y
9.44%
Profit CAGR
1Y
109.03%
3Y
52.68%
5Y
44.58%
10Y
35.86%
ROE
TTM
20.12%
3Y
27.91%
5Y
25.52%
10Y
20.99%
ROCE
TTM
26.21%
3Y
35.89%
5Y
33.16%
10Y
26.74%
Performance
MARKET LEADER
Valuation
OVERVALUED
Growth
EXCEPTIONAL
Profitability
HIGH MARGIN
Technicals
Bullish
Risk
MODERATE RISK
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
830.00 | 4,173 Cr | 79.88 | 3.28 | 0.00 | 4.10 | 4.28 | 3.02 | |
171.60 | 4,034 Cr | — | 14.34 | 0.00 | -75.33 | -75.33 | -62.80 | |
691.25 | 4,024 Cr | 32.33 | 3.94 | 0.00 | 12.19 | 13.06 | 7.36 | |
2312.10 | 3,923 Cr | 35.20 | 7.08 | 1.01 | 20.12 | 26.21 | 30.53 | |
230.50 | 3,525 Cr | 23.59 | 0.55 | 0.00 | 2.14 | 3.12 | 1.23 | |
353.25 | 3,464 Cr | 60.81 | 5.49 | 0.03 | 9.02 | 10.81 | 4.48 | |
463.75 | 3,270 Cr | 22.45 | 1.34 | 0.00 | 5.98 | 6.30 | 2.49 |
Turned 1 L into 6.24 L in last 5 Years
Regulatory Filing
1 day ago
Regulation 30(5) Disclosure
The Board of RPG Life Sciences has authorized key managerial personnel for determining materiality of events and disclosures as per SEBI regulations.
Corporate Action
1 day ago
Proposed Incorporation of Wholly Owned Subsidiary
RPG Life Sciences Limited announced the unanimous approval for the incorporation of 'RPG Active Pharma Limited', a wholly owned subsidiary, by the Board of Directors during their meeting on December 15, 2025.
Change in Management
1 day ago
Appointment of CFO and Formation of Wholly Owned Subsidiary
RPG Life Sciences Limited has appointed Mr. Amol Lone as Chief Financial Officer and announced the incorporation of a wholly owned subsidiary, RPG Active Pharma Limited.
Board Meeting Outcome
1 day ago
Board Meeting Outcomes from December 15, 2025
RPG Life Sciences Limited approved the appointment of a new CFO, the incorporation of a wholly owned subsidiary, and plans for a business transfer of its API segment.
